Funding for this research was provided by:
Fundació Marató de TV3 (20141610)
Fondo de Investigaciones Sanitarias, FEDER (15/00377)
Fondo de Investigaciones Sanitarias (FIS 14/00203)
National Institutes of Health (NIH RO1NS077851)
Received: 22 April 2016
Revised: 2 June 2016
Accepted: 12 June 2016
First Online: 29 June 2016
Compliance with ethical standards
: This study was partly supported by grants from Fundació Marató de TV3 to EG (grant no. 20141610), Fondo de Investigaciones Sanitarias, FEDER, (FIS 15/00377, FG), (FIS 14/00203, JD) and CIBERER (JD), Madrid, Spain, Fundació CELLEX (JD), and NIH RO1NS077851 (JD).
: JD receives royalties from licensing fees to Athena diagnostics for a patent for the use of Ma2 and autoantibody test, and from licensing fees to Euroimmun for patents for the use of NMDAR and GABAbR as autoantibody tests, and licensing fees for the use of DPPX, GABAaR, and IgLON5 antibodies as diagnostic tests. JD has received a research grant from Euroimmun. FG receives royalties from licensing fees to Euroimmun for the use of IgLON5 as a diagnostic test.
: EG, RH, HL, JH, TD, MP, JP, BH, GR, JS, HB, TR, GK declare that they have no conflict of interest.